Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 94Prostatic Neoplasms, Castration-Resistant 10Neoplasm Metastasis 8Breast Neoplasms 8Neoplasms 7Triple Negative Breast Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Bulbo-Spinal Atrophy, X-Linked 3Adenocarcinoma 3mCRPC 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostate Adenocarcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Bites and Stings 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1

Interventions

enzalutamide 1Radiosurgery 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Prostate Cancer × enzalutamide × 1 year × Clear all
NCT07198633 2026-06-02

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Recruiting
212 enrolled
Genitourinary

Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡